Three abstracts focused on improving clinical trials processes have been selected for formal presentation at the Association of American Cancer Institutes’ (AACI) Clinical Research Innovation (CRI) annual meeting, July 9-11, in Chicago.
The CRI Steering Committee and CRI Education Committee reviewed 66 submissions. Authors of the winning abstracts represent AACI member cancer centers Memorial Sloan Kettering Cancer Center; Hollings Cancer Center, Medical University of South Carolina; and Masonic Cancer Center, University of Minnesota.
The concepts presented in the abstracts illustrate the creative and thoughtful methods that are being employed at AACI cancer centers to address clinical trials process issues.
The three winning abstracts, which will be presented individually during a formal meeting program session, are:
First Place: “Electronic Informed Consent (eIC) Platform for Clinical Trials: An Operational Model and Suite of Tools for Consent Authoring, Obtaining Informed Consent, and Managing Consent Documents” J. Lengfellner, M. Buckley, M. Koch, H. Pacheco, J. Levine, C. Hoidra, D. Damron, C. Houston, R. Cambria, A. Rodavitch, P. Sabbatini, E. Cottington Memorial Sloan Kettering Cancer Center
Second Place: “Implementation of an Oncology Clinical Research Merit-Based Recognition Program for Physicians” T. Adrales Bentz, C. Britten, D. Berrier, D. Marshall Hollings Cancer Center, Medical University of South Carolina
Third Place: “MNCCTN: Challenges to Opening a State-Wide Network and the Pathway to Success – A 2-Year Perspective” M.L. Rahne, R. Leed, C. Stibbe, J. Alkire Masonic Cancer Center, University of Minnesota
All abstract authors have been invited to present a poster at the 11th Annual AACI CRI Meeting poster session.
The AACI CRI annual meeting program aligns with AACI’s strategic goal of stimulating cancer center interactions to maximize resources by creating opportunities for peer-to-peer networking and collaboration. CRI participants fill a variety of leadership roles and possess a comprehensive understanding of the clinical trials system.